Extrawell Pharmaceutical (HKG:0858) expects to post a loss of at least HK$950 million for fiscal 2026, compared with a profit in fiscal 2025, according to a Tuesday Hong Kong bourse filing.
The company attributed the expected swing to an unrealized loss on its investment in convertible bonds issued by Starcoin Group (HKG:0399), whose shares were suspended from trading in May, as well as impairment provisions on its interest in an associate and related loan receivables.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.